Skin Metastases from Neuroendocrine Tumors Can Respond to Targeted Peptide Radionuclide Therapy (PRRT)
Cutaneous metastases from visceral neuroendocrine tumors are rare but can respond to surgical resection and peptide receptor radionuclide therapy (PRRT), highlighting the importance of histologic diagnosis.
Quick Facts
What This Study Found
Cutaneous neuroendocrine metastases from visceral origins, though rare, can be managed with surgical resection and peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors.
Key Numbers
Single patient case; combination of surgical resection and targeted radionuclide therapy.
How They Did This
Case series documenting cutaneous neuroendocrine metastases of visceral origin, their histologic characterization, and treatment response to surgery and PRRT.
Why This Research Matters
Skin lesions from neuroendocrine tumors can be misdiagnosed, delaying treatment. Recognizing these as metastatic NETs opens the door to targeted peptide therapies (PRRT) that can control even distant disease.
The Bigger Picture
PRRT represents one of the clearest successes of peptide-targeted medicine — using the tumor's own somatostatin receptors as a homing beacon for radiation therapy. This case series extends PRRT's demonstrated utility to the uncommon scenario of cutaneous metastases.
What This Study Doesn't Tell Us
Case series with limited patient numbers — cannot establish response rates or survival benefit. Selection bias toward patients with somatostatin receptor-positive tumors. Generalizability limited to well-differentiated NETs.
Questions This Raises
- ?Should cutaneous metastases from NETs change staging or prognosis expectations?
- ?Can PRRT prevent further cutaneous metastasis in patients with known visceral NETs?
- ?How should unexplained skin nodules in NET patients be evaluated?
Trust & Context
- Key Stat:
- Extremely rare Cutaneous metastases from visceral NETs, treated successfully with PRRT and surgery
- Evidence Grade:
- Preliminary evidence — case series documenting a rare presentation. Valuable for clinical awareness but insufficient for treatment guidelines.
- Study Age:
- Published in 2024. Reflects current PRRT and NET management approaches.
- Original Title:
- Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy.
- Published In:
- Case reports in dermatological medicine, 2024, 8873822 (2024)
- Authors:
- Tung-Hahn, Eleanor, El-Haddad, Ghassan, Strosberg, Jonathan(2)
- Database ID:
- RPEP-09415
Evidence Hierarchy
Frequently Asked Questions
Can neuroendocrine tumors spread to the skin?
Yes, though it's very rare. NETs usually spread to the liver, lymph nodes, and lungs. When they do appear in the skin, it typically means the cancer has progressed significantly. However, even these metastases can sometimes be treated with targeted peptide radiation therapy.
What is PRRT and how does it work?
Peptide receptor radionuclide therapy (PRRT) uses radioactive molecules attached to peptides that bind to receptors on tumor cells — specifically somatostatin receptors. It's like a guided missile: the peptide finds the tumor, and the radiation destroys it, while sparing surrounding healthy tissue.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09415APA
Tung-Hahn, Eleanor; El-Haddad, Ghassan; Strosberg, Jonathan. (2024). Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy.. Case reports in dermatological medicine, 2024, 8873822. https://doi.org/10.1155/2024/8873822
MLA
Tung-Hahn, Eleanor, et al. "Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy.." Case reports in dermatological medicine, 2024. https://doi.org/10.1155/2024/8873822
RethinkPeptides
RethinkPeptides Research Database. "Cutaneous Neuroendocrine Metastases of Visceral Origin Respo..." RPEP-09415. Retrieved from https://rethinkpeptides.com/research/tung-hahn-2024-cutaneous-neuroendocrine-metastases-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.